

# Clinical trials of elinogrel

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 acute myocardial infarction

Trial	Treatments	Patients	Trials design and methods
<b>elinogrel vs placebo</b>			
<b>ERASE-MI , 2009</b> n=34/36 follow-up: 30-37 days	elinogrel 10, 20, 40, or 60 mg as a single intravenous bolus versus placebo	STEMI patients	Parallel groups double blind
<b>elinogrel vs error</b>			
<b>INNOVATE</b> <i>ongoing</i> [NCT00751231] n=NA follow-up:	-	-	

└ More details and results :

- antiplatelets drug for acute myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q390>

## References

### ERASE-MI, 2009:

Berger JS, Roe MT, Gibson CM, Kilaru R, Green CL, Melton L, Blankenship JD, Metzger DC, Granger CB, Gretler DD, Grines CL, Huber K, Zeymer U, Buszman P, Harrington RA, Armstrong PW Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Am Heart J 2009;158:998-1004.e1 [19958867]

### INNOVATE, :

ongoing trial NCT00751231

## 2 acute coronary syndrome

Trial	Treatments	Patients	Trials design and methods
<b>elinogrel vs placebo</b>			

continued...

Trial	Treatments	Patients	Trials design and methods
ERASE-MI , 2009 n=34/36 follow-up: 30-37 days	elinogrel 10, 20, 40, or 60 mg as a single intravenous bolus versus placebo	STEMI patients	Parallel groups double blind
<b>elinogrel vs error</b>			
INNOVATE <i>ongoing</i> [NCT00751231] n=NA follow-up:	-	-	

More details and results :

- New P2Y12 Inhibitors for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q455>
- antiplatelets drug for acute coronary syndrome in STEMI patients at <http://www.trialresultscenter.org/go-Q564>

## References

### ERASE-MI, 2009:

Berger JS, Roe MT, Gibson CM, Kilaru R, Green CL, Melton L, Blankenship JD, Metzger DC, Granger CB, Gretler DD, Grines CL, Huber K, Zeymer U, Buszman P, Harrington RA, Armstrong PW Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Am Heart J 2009;158:998-1004.e1 [19958867]

### INNOVATE, :

ongoing trial NCT00751231

## 3 percutaneous coronary intervention

Trial	Treatments	Patients	Trials design and methods
<b>elinogrel vs clopidogrel</b>			
INNOVATE PCI [NCT00751231] n=NA follow-up:	-	-	

More details and results :

- antithrombotics for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q63>

## References

### INNOVATE PCI, :

Welsh RC, Rao SV, Zeymer U, Thompson VP, Huber K, Kochman J, McClure MW, Gretler DD, Bhatt DL, Gibson CM, Angiolillo DJ, Gurbel PA, Berdan LG, Paynter G, Leonardi S, Madan M, French WJ, Harrington RA A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. *Circ Cardiovasc Interv* 2012;5:336-46 [22647518]

Angiolillo DJ, Welsh RC, Trenk D, Neumann FJ, Conley PB, McClure MW, Stephens G, Kochman J, Jennings LK, Gurbel PA, Wjcik J, Dabrowski M, Saucedo JF, Stumpf J, Buerke M, Broderick S, Harrington RA, Rao SV Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. *Circ Cardiovasc Interv* 2012;5:347-56 [22619259]

Welsh RC, Rao SV, Zeymer U, Thompson VP, Huber K, Kochman J, McClure MW, Gretler DD, Bhatt DL, Gibson CM, Angiolillo DJ, Gurbel PA, Berdan LG, Paynter G, Leonardi S, Madan M, French WJ, Harrington RA A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. *Circ Cardiovasc Interv* 2012;5:336-46 [22647518]

Entry terms: elinogrel, PRT 060128, PRT060128, PRT-060128,